Some TIV formulations are approved for use in eligible children 6 months and older. The Ann Arbor strain LAIV (MedImmune, LLC, Gaithersburg, MD) was licensed in 2003 for use in eligible individuals aged 5–49 years. Initially, LAIV was not approved for use in children younger than 5 years because an increased rate of asthma and wheezing events was noted in young children in one study [3]. A subsequent study that was prospectively designed to evaluate wheezing showed an increased rate of medically attended wheezing selleck in LAIV-vaccinated

children aged <24 months, with no increase in LAIV-vaccinated children ≥24 months of age [4] and [5]. Based on this study, in 2007 the US Food and Drug Administration expanded its approval of LAIV to include children aged 24–59 months [6]. From the initial approval of LAIV through the 2011–2012 season, more than 50 million doses have been distributed for use in the United States, with use predominantly occurring among children, military personnel, and healthcare workers. During prelicensure clinical trials, the safety of LAIV was evaluated in 26,031 children aged

2–18 years, including data from 14 placebo-controlled studies (N = 10,693), 6 TIV-controlled studies (N = 4245) and 1 community-based open-label study (N = 11,096) [7] and [8]. Previous comparative studies of LAIV and TIV have generally demonstrated comparable safety of the 2 vaccines

among individuals ≥2 years of age, with most adverse reactions from either vaccine Akt inhibitor being mild, transient, and of minimal clinical significance [7]. At the time of the initial approval of LAIV in the United States, MedImmune committed to the US Food and Drug Administration to Modulators conduct a postmarketing evaluation of the safety of LAIV in 60,000 LAIV recipients 5–49 years of age, with 20,000 many individuals each aged 5–8 years, 9–17 years, and 18–49 years. The intent of this postmarketing study was to conduct a broad assessment of safety, evaluating all events and specific prespecified events. The current analysis describes the results among children 5–8 years and 9–17 years of age; results for adults 18–49 years of age will be reported separately. Kaiser Permanente (KP) health plan is a large integrated health maintenance organization with medical centers in multiple areas of the United States. The KP database was previously used to evaluate the safety of LAIV in a randomized, placebo-controlled study [3]. The current study was a prospective observational study and collected data from the Northern California, Hawaii, and Colorado KP sites, where inclusive membership totals approximately 4 million individuals. All medical care for members is provided through the health plan, and clinic visits and treatments are documented in comprehensive databases.